Patent ID: 9174975
Filing Date: 2015-11-03
Classification: A61K,A61P,C07D

Abstract:
1. A method for treating the negative symptoms of schizophrenia and/or the cognitive dysfunction of schizophrenia in a patient, which comprises orally administering a once daily dose of 5 mg to 120 mg of the active compound: (1R,2S,3R,4S)—N[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide of the formula (1): or a pharmaceutically acceptable salt thereof to a patient suffering from negative symptoms of schizophrenia and/or cognitive dysfunction of schizophrenia.